Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors

Eung Seok Lee, Youngsuk Lee, Dongjoo Suh, Jaesung Kang, Insun Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To evaluate the possibility of the targeted therapy for human epidermal growth factor receptor (HER)-2 and epidermal growth factor receptor (EGFR) in ovarian cancers, we evaluated HER-2 and EGFR gene amplification by using chromogenic in-situ hybridization method in ovarian common epithelial tumors. The increased gene copy number of HER-2 was found in 20 of 90 primary cancers (22.2%), but not in benign and borderline tumors. There were 3 trisomy (3.3%), 10 polysomy (11.1%), and 7 amplification (7.8%). The increased gene copy number of HER-2 was more common in mucinous (45.5%) and clear cell carcinomas (41.7%) than in serous (17.5%) and endometrioid carcinomas (0%), but without statistical significance. The increased copy number of EGFR gene was found in 2 of 24 borderline tumors (8.3%) and 34 of 90 malignant tumors (37.8%), but none of benign tumors. There were 1 amplification (1.1%), 9 trisomy (10.0%), and 26 polysomy (28.9%). Serous (45.6%) and clear cell (50.0%) carcinomas showed more frequent EGFR gene copy number changes than in serous borderline tumors (11.8%), mucinous (9.1%), and endometrioid carcinomas (10%), but with statistical significance only between serous borderline tumors and serous carcinomas. Increased HER-2 gene copy number was not correlated with International Federation of Gynecology and Obstetrics stage as well as histologic and nuclear grades, whereas increased EGFR gene copy number was correlated with histologic and nuclear grade. From the above results, we conclude that chromogenic in-situ hybridization technique can be used in the evaluation of HER-2 and EGFR gene number changes in selecting the patients who need far more specific and effective therapeutic modalities, such as targeted therapy.

Original languageEnglish
Pages (from-to)69-74
Number of pages6
JournalApplied Immunohistochemistry and Molecular Morphology
Volume18
Issue number1
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

erbB-1 Genes
Gene Amplification
In Situ Hybridization
Gene Dosage
Neoplasms
Endometrioid Carcinoma
Carcinoma
erbB-2 Genes
Mucinous Adenocarcinoma
Trisomy
Gynecology
Epidermal Growth Factor Receptor
Ovarian Neoplasms
Obstetrics
Therapeutics

Keywords

  • CISH
  • EGFR
  • HER-2
  • Ovarian cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Cite this

Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors. / Lee, Eung Seok; Lee, Youngsuk; Suh, Dongjoo; Kang, Jaesung; Kim, Insun.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 18, No. 1, 01.01.2010, p. 69-74.

Research output: Contribution to journalArticle

@article{4fe3cacee1f04027aacee67d9553e92a,
title = "Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors",
abstract = "To evaluate the possibility of the targeted therapy for human epidermal growth factor receptor (HER)-2 and epidermal growth factor receptor (EGFR) in ovarian cancers, we evaluated HER-2 and EGFR gene amplification by using chromogenic in-situ hybridization method in ovarian common epithelial tumors. The increased gene copy number of HER-2 was found in 20 of 90 primary cancers (22.2{\%}), but not in benign and borderline tumors. There were 3 trisomy (3.3{\%}), 10 polysomy (11.1{\%}), and 7 amplification (7.8{\%}). The increased gene copy number of HER-2 was more common in mucinous (45.5{\%}) and clear cell carcinomas (41.7{\%}) than in serous (17.5{\%}) and endometrioid carcinomas (0{\%}), but without statistical significance. The increased copy number of EGFR gene was found in 2 of 24 borderline tumors (8.3{\%}) and 34 of 90 malignant tumors (37.8{\%}), but none of benign tumors. There were 1 amplification (1.1{\%}), 9 trisomy (10.0{\%}), and 26 polysomy (28.9{\%}). Serous (45.6{\%}) and clear cell (50.0{\%}) carcinomas showed more frequent EGFR gene copy number changes than in serous borderline tumors (11.8{\%}), mucinous (9.1{\%}), and endometrioid carcinomas (10{\%}), but with statistical significance only between serous borderline tumors and serous carcinomas. Increased HER-2 gene copy number was not correlated with International Federation of Gynecology and Obstetrics stage as well as histologic and nuclear grades, whereas increased EGFR gene copy number was correlated with histologic and nuclear grade. From the above results, we conclude that chromogenic in-situ hybridization technique can be used in the evaluation of HER-2 and EGFR gene number changes in selecting the patients who need far more specific and effective therapeutic modalities, such as targeted therapy.",
keywords = "CISH, EGFR, HER-2, Ovarian cancer",
author = "Lee, {Eung Seok} and Youngsuk Lee and Dongjoo Suh and Jaesung Kang and Insun Kim",
year = "2010",
month = "1",
day = "1",
doi = "10.1097/PAI.0b013e3181af7d3f",
language = "English",
volume = "18",
pages = "69--74",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors

AU - Lee, Eung Seok

AU - Lee, Youngsuk

AU - Suh, Dongjoo

AU - Kang, Jaesung

AU - Kim, Insun

PY - 2010/1/1

Y1 - 2010/1/1

N2 - To evaluate the possibility of the targeted therapy for human epidermal growth factor receptor (HER)-2 and epidermal growth factor receptor (EGFR) in ovarian cancers, we evaluated HER-2 and EGFR gene amplification by using chromogenic in-situ hybridization method in ovarian common epithelial tumors. The increased gene copy number of HER-2 was found in 20 of 90 primary cancers (22.2%), but not in benign and borderline tumors. There were 3 trisomy (3.3%), 10 polysomy (11.1%), and 7 amplification (7.8%). The increased gene copy number of HER-2 was more common in mucinous (45.5%) and clear cell carcinomas (41.7%) than in serous (17.5%) and endometrioid carcinomas (0%), but without statistical significance. The increased copy number of EGFR gene was found in 2 of 24 borderline tumors (8.3%) and 34 of 90 malignant tumors (37.8%), but none of benign tumors. There were 1 amplification (1.1%), 9 trisomy (10.0%), and 26 polysomy (28.9%). Serous (45.6%) and clear cell (50.0%) carcinomas showed more frequent EGFR gene copy number changes than in serous borderline tumors (11.8%), mucinous (9.1%), and endometrioid carcinomas (10%), but with statistical significance only between serous borderline tumors and serous carcinomas. Increased HER-2 gene copy number was not correlated with International Federation of Gynecology and Obstetrics stage as well as histologic and nuclear grades, whereas increased EGFR gene copy number was correlated with histologic and nuclear grade. From the above results, we conclude that chromogenic in-situ hybridization technique can be used in the evaluation of HER-2 and EGFR gene number changes in selecting the patients who need far more specific and effective therapeutic modalities, such as targeted therapy.

AB - To evaluate the possibility of the targeted therapy for human epidermal growth factor receptor (HER)-2 and epidermal growth factor receptor (EGFR) in ovarian cancers, we evaluated HER-2 and EGFR gene amplification by using chromogenic in-situ hybridization method in ovarian common epithelial tumors. The increased gene copy number of HER-2 was found in 20 of 90 primary cancers (22.2%), but not in benign and borderline tumors. There were 3 trisomy (3.3%), 10 polysomy (11.1%), and 7 amplification (7.8%). The increased gene copy number of HER-2 was more common in mucinous (45.5%) and clear cell carcinomas (41.7%) than in serous (17.5%) and endometrioid carcinomas (0%), but without statistical significance. The increased copy number of EGFR gene was found in 2 of 24 borderline tumors (8.3%) and 34 of 90 malignant tumors (37.8%), but none of benign tumors. There were 1 amplification (1.1%), 9 trisomy (10.0%), and 26 polysomy (28.9%). Serous (45.6%) and clear cell (50.0%) carcinomas showed more frequent EGFR gene copy number changes than in serous borderline tumors (11.8%), mucinous (9.1%), and endometrioid carcinomas (10%), but with statistical significance only between serous borderline tumors and serous carcinomas. Increased HER-2 gene copy number was not correlated with International Federation of Gynecology and Obstetrics stage as well as histologic and nuclear grades, whereas increased EGFR gene copy number was correlated with histologic and nuclear grade. From the above results, we conclude that chromogenic in-situ hybridization technique can be used in the evaluation of HER-2 and EGFR gene number changes in selecting the patients who need far more specific and effective therapeutic modalities, such as targeted therapy.

KW - CISH

KW - EGFR

KW - HER-2

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=76149123211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149123211&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e3181af7d3f

DO - 10.1097/PAI.0b013e3181af7d3f

M3 - Article

C2 - 19652593

AN - SCOPUS:76149123211

VL - 18

SP - 69

EP - 74

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 1

ER -